Condition
Ulcerative colitis news across medications, symptoms, monitoring, procedures, research, access, and daily life.
Page 36 of 40 · 1917 articles
If you have IBD — especially Crohn’s — this study suggests your long-term risk of needing dialysis or a kidney transplant may be higher than the general population. Certain treatments and prior bowel surgery were linked...
People with UC have higher rates of low bone density, which raises fracture risk. This study links altered hormones (leptin, ghrelin, IGF‑1) and inflammation to lower BMD in UC, suggesting metabolic pathways that could...
This trial tests whether raising the upadacitinib dose to 45 mg can recapture clinical response in people with ulcerative colitis who lost response on the 30 mg maintenance dose. If effective and safe, the approach could...
This trial tests palmitoylethanolamide (PEA), a commercially available supplement with anti-inflammatory actions, as an add-on treatment for mild-to-moderate ulcerative colitis.
Reports a rare mesenteric fibroinflammatory complication in a patient with UC who was in remission on vedolizumab, raising a hypothesis about possible associations worth further study.
Vitamin D supplementation is commonly considered in people with IBD because deficiency is frequent and low vitamin D may relate to inflammation.
The work identifies a genetic link (HLA‑DRB1*01:03) to anti‑IL‑10 autoantibodies and describes a small subgroup of IBD patients who may have a distinct immune mechanism driving disease—information that could matter for...
Lower hospitalization rates suggest upadacitinib may reduce severe disease events that require inpatient care, which matters to patients and clinicians aiming to avoid hospital stays and complications. Large real-world...
If confirmed, a simple blood marker (NLR) plus biopsy results could help identify UC patients at higher risk of relapse despite endoscopic improvement, which might guide monitoring or treatment choices.
The finding links a specific mucus-associated protein (HMGB1) to barrier defects in Crohn’s disease, which could help explain how bacteria reach and inflame tissue in active lesions and point to future biomarker or...
People with IBD commonly have musculoskeletal pain and need safe short-term pain options. This review suggests selective COX-2 inhibitors may be an option for selected patients in remission when monitored closely, but...
The study identifies a food-processing method (black tea processing) that increased flavonoids and improved outcomes in a mouse model of colitis, suggesting that specific dietary preparations might influence gut...
Phosphatidylcholines are implicated in IBD biology; identifying a gene that regulates PC metabolism could point to new mechanistic targets. If PRKAB1 modulates epithelial lipid metabolism relevant to inflammation, it may...
This preclinical study suggests a marine-derived collagen peptide fraction may strengthen intestinal barrier function, reduce oxidative stress, and partially restore gut microbiota in models of colitis — mechanisms...
Prednisone is a commonly used steroid for short-term control of IBD flares; changes or reaffirmations in its FDA label affect prescribing and safety guidance that patients and clinicians rely on.
If hospital-treated infections raise later IBD risk—especially in people with certain immune-related genetic variants—this supports a multi-hit model of IBD and could eventually help identify higher-risk individuals...
The project could reveal a new neuro-immune circuit (IL-17A acting on enteric neurons) that promotes tissue protection during intestinal inflammation, suggesting novel non-immunosuppressive therapeutic targets for IBD.
Understanding how commensal-specific CD8+ T cells are generated and become pathogenic could reveal new mechanisms contributing to IBD, pointing to future therapeutic targets. The project aims to clarify immune–microbiota...
This FDA label update adds or confirms ABRILADA (an adalimumab product) as an approved TNF-blocker option for Crohn’s disease (including children ≥6) and ulcerative colitis (adults). It emphasizes infection and...
People with longstanding ulcerative colitis face higher colorectal cancer risk; this project focuses on a specific immune/stromal cell population (ST2+ cells responding to IL-33) that may help explain how chronic...
The label confirms adalimumab is approved for Crohn’s disease and ulcerative colitis and includes boxed safety warnings—information that directly affects patients considering or taking this TNF‑blocking biologic.
This is an FDA drug-label record for ustekinumab that lists approved uses for Crohn’s disease and ulcerative colitis and highlights safety precautions (infections, TB screening, malignancy risk, and vaccine...
An FDA label update names risankizumab (SKYRIZI) as a treatment option for adults with moderately to severely active Crohn’s disease and ulcerative colitis and highlights new or emphasized safety monitoring (liver tests,...
This project studies a novel enzyme target (GCPII) that is reportedly upregulated in IBD and may change glutamate signaling and barrier function; understanding it could point to new treatment strategies for people whose...
The FDA label update for tofacitinib lists ulcerative colitis among approved uses and highlights serious safety warnings that are directly relevant to people with IBD considering or taking this oral JAK inhibitor.
This is the FDA DailyMed label for dexamethasone, which lists gastrointestinal uses including short-term use in ulcerative colitis and regional enteritis (Crohn's disease). Patients with IBD may be prescribed...
This is an FDA label entry for YUFLYMA (an adalimumab product) that confirms Crohn’s disease and ulcerative colitis are listed indications and reiterates serious-infection and malignancy warnings for TNF blockers....
The survey highlights wide variation in how rectal stumps are assessed and managed after colectomy in children with UC, indicating uncertainty and a gap in standardised care that could affect outcomes and follow-up...
The study identifies a plant extract that reduced colitis-like injury in mice and altered gut microbes and intestinal barrier markers, which could inform future preclinical work. For people with IBD, this is early-stage...
Researchers are exploring plant-derived polysaccharides as potential therapies that might reduce inflammation and protect the intestinal barrier. For people with UC, therapies that reduce pyroptosis and restore...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Medications. The original article is from Therapy.
The trial is testing risankizumab alone and in combination with investigational ABBV antibodies for moderate-to-severe Crohn’s disease and ulcerative colitis — findings could inform future treatment choices and...
The study suggests measurable retinal and choroidal microvascular differences in people with IBD versus controls, which could point to systemic vascular effects of inflammation and offer noninvasive biomarker...
An obituary listing Crohn’s disease and ulcerative colitis as the cause of death is a personal account that can resonate with others affected by IBD and highlights real-world impact on individuals and families.
The study suggests that people with ulcerative colitis who consume diets higher in antioxidant capacity had lower measured disease activity, which could point to diet as a modifiable factor worth exploring alongside...
This study shows that patients' comfort partly explains how clinical disease activity affects quality of life in ulcerative colitis, suggesting comfort-focused nursing care could help patients feel better even when...
The study identifies a sizable group of patients in Latin America with difficult-to-treat IBD—especially Crohn’s disease—highlighting higher disease severity, younger onset, and longer diagnostic delays that can affect...
Researchers are exploring circRNAs as new molecular players in IBD inflammation; that could lead to future biomarker tests or novel treatments targeting immune pathways relevant to Crohn’s disease and ulcerative colitis.
This study suggests a traditional processing method may change a common herbal used for UC so it works better in mouse and cell models, and it proposes a specific molecular pathway (LCN2‑mediated pyroptosis) that could...
This preclinical study suggests a ginseng-derived polysaccharide reduced inflammation and tissue injury in cell and mouse models of colitis, which could eventually inform dietary supplements or therapeutic research...
Work participation and job retention are common concerns for people living with IBD. This study will measure how IBD affects work ability, fatigue, mental health, and return-to-work barriers, and aims to create...
A long-term study that profiles immune cells, genes, diet, and the microbiome could help identify biomarkers that predict flares or response to therapy, which matters to people living with Crohn’s or ulcerative colitis.
A new Phase 2 trial is testing MK-8690 as a potential subcutaneous treatment for moderate–severe ulcerative colitis, with clinical remission at 12 weeks as the primary goal. Positive results could point to an additional...
Researchers identify a gut microbe (Sutterella species) that may worsen intestinal inflammation by blocking AhR-driven IL-22 and IL-17 responses—pathways that help protect the gut lining.
The study shows rapidly rising IBD healthcare costs driven mainly by growing prevalence and biologic therapy spending, which can affect access, insurance coverage, and healthcare planning for people with Crohn’s and...
This study describes a new oral immunoproteasome inhibitor (ent-F10) with preclinical activity in animal models of ulcerative colitis and rheumatoid arthritis, highlighting a potential new drug-development direction that...
This paper links specific features of the gut bacterial flagellome to TLR5-driven immune activation and reports a disease-associated shift in flagellin profiles in Crohn’s disease and ulcerative colitis, suggesting...
This study reports real-world data on mirikizumab in adults with ulcerative colitis, focusing on clinical and endoscopic remission and inflammatory markers — outcomes patients and clinicians use to judge treatment...
